Selected References:

• Auyeung-Kima DJ, et al. 2009. Developmental and peripostnatal study in cynomolgus monkeys with belimumab, a monoclonal antibody directed against B-lymphocyte stimulator. Reproductive Toxicology, 28:443-455.
• Beaulieu DB, et al. 2018. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin Gastroenterol Hepatol, 16(1):99–105.
• Benlysta® Prescribing Information. 2023. Available online at https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Benlysta/pdf/BENLYSTA-PI-MG-IFU.PDF.
• 2013. Use of intravenous (IV) benlysta in pregnant patients with systemic lupus erythematosus (SLE). As cited in Ostensen M. 2014. Safety issues of biologics in pregnant patients with rheumatic diseases. Ann NY Acad Sci, 1317:32-38.
• Julsgaard M, et al. 2016. Concentrations of adalimumab and infliximab in mothers and newborns, and effects on infection. Gastroenterology, 151:110-119.
• Kathpalia P, et al. 2016. Detectable drug levels in infants exposed to biologics: so what? Gastroenterology, 151:25–26.
• Kao JH, et al. 2021. Pregnancy outcomes in patients treated with belimumab: report from real-world experience. Semin Arthritis Rheum, 51(5):963-968.
• Martin Bortlik, et al. 2014. Impact of anti–tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children. Inflammatory Bowel Diseases, 20(3):495–501.
• Miller RK, et al. 2014. ABSTRACT. Preliminary data from the Belimumab Pregnancy Registry: international prospective cohort study of pregnancy outcomes. OTIS/ENTIS meeting, Toronto, Canada.
• Peart E, Clowse MEB. 2014. Systemic lupus erythematosus and pregnancy outcomes: an update and review of the literature. Curr Opin Rheumatol, 26:118-123.
• Sandhu VK, et al. 2015. Monoclonal antibodies, systemic lupus erythematosus, and pregnancy. J Rheumatol, 42:728-730.
• Skorpen, GC. et al. 2016. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis, 75(5):795-810.
• Vela-Casasempere, P, et al. 2024. Considering belimumab during pregnancy: a more viable option over time. Lupus 33(7): 700-715.

Selected References:

• Ching, NS, et al. 2019. Prospective surveillance of pediatric invasive group A streptococcus infection. J Pediatric Infect Dis Soc 8:46-52.
• Hamilton SM, et al. 2013. Pregnancy-Related Group A Streptococcal Infections: Temporal Relationships Between Bacterial Acquisition, Infection Onset, Clinical Findings, and Outcome. Clin Infect Dis 57(6): 870-876.
• Harris K, et al. 2023. Outcomes and management of pregnancy and puerperal group A streptococcal infections: A systematic review. Acta Obstetricia et Gynecologica Scandinavica 102(2): 138-157.
• Jawa G, et al. Recurrent late-onset group B Streptococcus sepsis in a preterm infant acquired by expressed breastmilk transmission: a case report. Breastfeed Med. 8(1):134-6.
• Kim SY, Yi DY. 2020. Analysis of the human breast milk microbiome and bacterial extracellular vesicles in healthy mothers. Exp Mol Med 52(8): 1288-1297.
• Knowles SJ, et al. 2015. Maternal sepsis incidence, aetiology and outcome for mother and fetus: a prospective study. BJOG 122(5): 663-671.
• Olver WJ, et al. 2000. Neonatal group B streptococcal disease associated with infected breast milk. Arch Dis Child Fetal Neonatal Ed 83:F48-49.
• Saito R, et al. 2017. Late onset neonatal sepsis caused by group A streptococcus. Br J Hosp Med (Lond). 78(3):170-171.
• Sherwood E, et al. 2022. Invasive group A streptococcal disease in pregnant women and young children: a systematic review and meta-analysis. The Lancet Infectious Diseases 22(7): 1076-1088.
• Sindi AS, et al. 2023. Characterisation of human milk bacterial DNA profiles in a small cohort of Australian women in relation to infant and maternal factors. PLoS One 18(1): e0280960.
• Sokou R, et al. 2023. Group A Streptococcus Infection in Neonatal Population: A Systematic Review of The Literature. J Clin Med 12(22): 6974.
• Wong NX, et al. 2019. A cluster of pediatric invasive group A streptococcus disease in Melbourne, Australia, coinciding with a high-burden influenza season. J Pediatr Infect Dis 14:213-218.
• Zayek MM, et al. 2002. Breast milk as a major source for “late onset” GBS infection in preterm infants. Pediatr Res 51:304A.

Selected References:

• No authors listed. 2024. Bimekizumab (Bimzelx) for psoriasis. Med Lett Drugs Ther. 22;66(1694):11-13.
• Product Information: BIMZELX(R) subcutaneous injection, bimekizumab subcutaneous injection. UCB Inc (per FDA), Smyrna, GA, 2023. https://www.bimzelx.com/prescribing-information.pdf.

Selected References:

• American College of Obstetricians and Gynecologists (ACOG). 2019. ACOG Committee Opinion, number 782. Prevention of Group B Streptococcal early-onset disease in newborns: 2019. Obstet Gynecol, 134(1):e19-e40.
• Bae GE, et al. 2016. Acute placental villitis as evidence of fetal sepsis: an autopsy case report. Pediatr Dev Pathol 19(2): 165-168.
• Cape A, et al. 2013. Peripartum bacteremia in the era of group B streptococcus prophylaxis. Obstet Gynecol. 121(4):812-818.
• Charles D, Larsen B. 10986. Streptococcal puerperal sepsis and obstetric infections: a historical perspective. Rev Infect Dise 8:411-422.
• Daskalakis G, et al. 2023. Maternal Infection and Preterm Birth: From Molecular Basis to Clinical Implications. Children (Basel). 10(5):907.
• Giakoumelou S, et al. 2016. The role of infection in miscarriage. Hum Reprod Update. 22(1):116-33.
• Kenchington AL, Lamont RF. 2017. Group B streptococcal immunisation of pregnant women for the prevention of early and late onset Group B streptococcal infection of the neonate as well as adult disease. Expert Rev Vaccines. 16(1):15-25.
• Nan C, et al. 2015. Maternal group B streptococcus-related stillbirth: a systemic review. BJOG 122(11): 1437-1445.
• Oghbaei H, et al. 2020. Effects of bacteria on male fertility: spermatogenesis and sperm function. Life Sciences 256: 117891.
• Olver WJ, et al. 200. Neonatal group B streptococcal disease associated with infected breast milk. Arch Dis Child Fetal Neonatal Ed 83:F48-49.
• Polcwiartek LB, et al. 2021. Early-onset sepsis in term infants admitted to neonatal intensive care units (2011-2016). J Perinatol. 1(1):157-163.
• Petersen KB, et al. 2014. Increasing prevalence of group B streptococcal infection among pregnant women. Dan Med J. 2014 Sep;61(9):A4908.
• Ravel J, et al. 2021. Bacterial vaginosis and its association with infertility, endometritis, and pelvic inflammatory disease. Am J Obstet Gyn 224(3): 251-257.
• Staford IA, et al. 2018. The strong correlation between neonatal early onset group B streptococcal disease and necrotizing enterocolitis. Eur J Obstet Gynecol Reprod Biol 223:93-97.
• S. Centers for Disease Control and Prevention (CDC). 2024. Clinical Overview of Group B Strep Disease. Available at: https://www.cdc.gov/group-b-strep/hcp/clinical-overview/index.html. Accessed September 30 2024.
• Verani JR, et al; Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). 2010. Prevention of perinatal group B streptococcal disease–revised guidelines from CDC, 2010. MMWR Recomm Rep. 59(RR-10):1-36.

Selected References:

• Ito S, et al. 1993. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 168:1393-9. Messinis IE, et al. 1985. Histamine H1 receptor participation in the control of prolactin secretion in postpartum. J Endocrinol Invest. 8:143-6.
• Pontiroli AE, et al. 1981. The effect of histamine and H1 and H2 receptors on prolactin and luteinizing hormone release in humans: sex differences and the role of stress. J Clin Endocrinol Metab. 52:924-8.
• Product information. Azelastine Nasal. Perrigo New York, 2024. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=82610437-25f4-4ae0-9d6a-381e9932f87d.
• Suzuki Y, et al. 1981. Teratology and reproduction studies of azelastine, a novel antiallergic agent, in rats and rabbits. Arzneim-Forsch. 31:1225-30.
• Tatsumi K, et al. 1980. Studies of metabolic fate of a new antiallergic agent, azelastine. Jpn J Pharmacol. 30:37-48.